Kalaris Therapeutics Inc (KLRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -9,057 | -3,407 | -190,418 | -130,722 | -86,450 |
| Depreciation Amortization | N/A | N/A | 398 | 257 | 171 |
| Accounts receivable | N/A | N/A | -49 | -77 | 51 |
| Accounts payable and accrued liabilities | -1,624 | -1,161 | -2,512 | 3,045 | 4,908 |
| Other Working Capital | -2,248 | -2,076 | 2,025 | 4,660 | 7,742 |
| Other Operating Activity | 4,437 | 2,123 | 66,105 | 29,121 | 14,338 |
| Operating Cash Flow | $-8,492 | $-4,521 | $-124,451 | $-93,716 | $-59,240 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | 37,985 | 12,767 | 79,618 |
| Investing Cash Flow | $N/A | $N/A | $37,985 | $12,767 | $79,618 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 9,993 | 4,993 | N/A | N/A | N/A |
| Common Stock Issued | N/A | N/A | 70,495 | 70,484 | 70,484 |
| Other Financing Activity | 1,569 | 1,586 | 0 | 0 | 0 |
| Financing Cash Flow | $11,562 | $6,579 | $70,495 | $70,484 | $70,484 |
| Beginning Cash Position | 3,169 | 3,169 | 106,944 | 106,944 | 106,944 |
| End Cash Position | 6,239 | 5,227 | 90,973 | 96,479 | 197,806 |
| Net Cash Flow | $3,070 | $2,058 | $-15,971 | $-10,465 | $90,862 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,492 | -4,521 | -124,451 | -93,716 | -59,240 |
| Free Cash Flow | -8,492 | -4,521 | -124,451 | -93,716 | -59,240 |